Clinical Trials

Clinical Trial Detail

Return to search results.

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Complete title: Targeted Therapy of Bronchiolitis Obliterans Syndrome (BOS)

Research Study Number       2367.00
Principal Investigator       Guang-Shing Cheng
Phase       II

Look up trial at NIH

Research Study Description

This phase II trial studies how well giving fluticasone propionate, azithromycin, and montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans who previously underwent stem cell transplant. FAM may be an effective treatment for bronchiolitis obliterans

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 6 Years and older

Genders Eligible for Study: Both

- New diagnosis of bronchiolitis obliterans syndrome (BOS) after HCT within 3 months of study enrollment: for this study, BOS is defined as:

- Forced expiratory volume in 1 second (FEV1) < 75% of the predicted normal and FEV1 to slow or inspiratory vital capacity ratio (FEV1/SVC or FEV1/IVC) =< 0.7, both measured before and after administration of bronchodilator


- Pathologic diagnosis of BOS demonstrated by lung biopsy

- The baseline absolute FEV1 must be >= 10% lower than the pre-transplant absolute FEV1 as defined by the pre-transplant FEV1 minus the baseline FEV1, both measured before administration of a bronchodilator

- Participant (or parent/guardian) has the ability to understand and willingness to sign a written consent document

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Recurrent or progressive malignancy requiring anticancer treatment

- Known history of allergy to or intolerance of montelukast, zafirlukast, azithromycin, erythromycin, or clarithromycin

- Pregnancy or nursing; all females of childbearing potential must have a negative serum or urine pregnancy test < 7 days before study drug administration

- Transaminases > 5 X upper limit of normal (ULN)

- Total bilirubin > 3 X ULN

- Chronic treatment with any inhaled steroid for > 1 month in the past three months

- Treatment with montelukast or zafirlukast for > 1 month during the past three months

- Treatment with prednisone at > 1.2 mg/kg/day (or equivalent steroid)

- Treatment with rifampin or phenobarbital, aspirin at doses > 325 mg/day, or ibuprofen at doses > 1200 mg/day

- Treatment with any Food and Drug Administration (FDA) non approved study medication within the past 4 weeks; off-label treatment with an FDA-approved medication is allowed

- Chronic oxygen therapy

- Evidence of any viral, bacterial or fungal infection involving the lung and not responding to appropriate treatment

- Clinical asthma (variable and recurring symptoms of airflow obstruction and bronchial hyper-responsiveness)

- Any condition that, in the opinion of the enrolling investigator, would interfere with the subject's ability to comply with the study requirements

- Uncontrolled substance abuse or psychiatric disorder

- Inability to perform pulmonary function tests (PFT) reliably, as determined by the enrolling investigator or PFT lab

- Life expectancy < 6 months at the time of enrollment as judged by the enrolling investigator

- Baseline post-bronchodilator FEV1 < 20% of predicted normal before or after albuterol

Other exclusion criteria may apply.

Research Study Number       2367.00
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Hematologic Malignancies; Chronic Graft Versus Host Disease (cGVHD)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.